| __timestamp | Opthea Limited | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2652041 | 504755000 |
| Thursday, January 1, 2015 | 2361587 | 838526000 |
| Friday, January 1, 2016 | 4472869 | 1177697000 |
| Sunday, January 1, 2017 | 5030957 | 1320433000 |
| Monday, January 1, 2018 | 4988941 | 1556200000 |
| Tuesday, January 1, 2019 | 5196412 | 1834800000 |
| Wednesday, January 1, 2020 | 6652774 | 1346000000 |
| Friday, January 1, 2021 | 18418247 | 1824900000 |
| Saturday, January 1, 2022 | 24827066 | 2115900000 |
| Sunday, January 1, 2023 | 41896408 | 2631300000 |
| Monday, January 1, 2024 | 15488619 | 2954400000 |
Data in motion
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Opthea Limited have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Regeneron consistently reported higher SG&A expenses, peaking at approximately $2.63 billion in 2023. This reflects a strategic investment in growth and market expansion. In contrast, Opthea's SG&A expenses, although significantly lower, surged by over 1,500% from 2014 to 2023, indicating a rapid scale-up phase.
While Regeneron's substantial SG&A outlay underscores its established market presence, Opthea's leaner approach highlights its agility and focus on efficient resource allocation. As the industry evolves, these strategies will play pivotal roles in shaping their competitive edges.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for AstraZeneca PLC and Opthea Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Opthea Limited
Operational Costs Compared: SG&A Analysis of Corcept Therapeutics Incorporated and Opthea Limited
Operational Costs Compared: SG&A Analysis of Opthea Limited and Apellis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and PTC Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Opthea Limited and Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Opthea Limited vs Wave Life Sciences Ltd.
Opthea Limited or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Opthea Limited or Xencor, Inc.